智通财经APP获悉，2026年1月12日晚间，药明康德(603259.SH/02359)发布了2025年度业绩预增公告。公司预计2025年全年营业收入约454.56亿元，创下历 史新高。 除了创记录的营业收入，药明康德的利润层面，三个口径下关键指标亦实现高于营收的增速攀升，经调整non-IFRS归母净利润、归母净利润及扣非后归母净 利润，分别同比增长约41.33%、102.65%及32.56%。 此前，药明康德已在三季度时第二次上调了全年经营目标。公司表示，紧抓客户需求、业务模式和管理执行的确定性，进一步上调全年业绩指引，预计2025 年持续经营业务重回双位数增长，增速上调至17~18%，公司整体收入上调至435~440亿元。 ...

Core Viewpoint - WuXi AppTec has reported record-high revenue and profit figures for the fiscal year 2025, indicating strong financial performance and commitment to shareholder value through significant cash dividends [1] Financial Performance - The company announced that its revenue and profit metrics have reached historical highs, with basic earnings per share doubling to 6.70 yuan per share [1] - The expected net profit attributable to shareholders for 2025 is projected to exceed 57 billion yuan, leading to record cash dividends for shareholders [1] Shareholder Value - WuXi AppTec has maintained a leading cash dividend payout ratio of 30% since its listing, reflecting its commitment to returning value to shareholders [1] - The company plans to unlock a total of 2.5 billion Hong Kong dollars in H-share incentives, contingent upon achieving specific revenue targets [1] Incentive Plans - The core unlocking conditions for the 2025 H-share incentive trust plan have been met, with revenue targets set at 42 billion yuan and 43 billion yuan for additional stock grants [1] - The incentive plan aims to foster long-term development and alignment of interests between core talent and the company [1]

根据统计，上市以来的七年时间里，药明康德通过现金分红、回购及注销股份的方式，累计回馈投资者 达到200亿元，超过了公司过去七年累计净利润的40%。 在归母净利润、每股收益达成新高的背景下，药明康德2025年度现金分红亦有望创下新高。按照此前， 公司在三季度业绩交流会上曾表示，上市以来一贯维持约30%的现金分红比例。根据本次预告的归母净 利润测算，2025年度现金分红总额预计将突破57亿元。 智通财经APP获悉，1月12日晚间，药明康德(603259.SH/02359)披露了其2025年度预增公告。公告显 示，公司预计全年营业收入约456.56亿元，同比增长约15.84%；其中持续经营业务收入同比增长约 21.4%。盈利方面，经调整non-IFRS归母净利润、归母净利润、扣非归母净利润分别同比增长约 41.33%、102.65%及32.56%，基本每股收益同样翻倍达到6.7元。 ...

Group 1 - The core viewpoint of the article is that WuXi AppTec (603259.SH/02359) has announced a significant increase in its revenue forecast for the year 2025, projecting approximately 45.456 billion yuan, marking a historical high [1] - The company has raised its annual performance guidance for the second time in the third quarter, indicating a strong focus on customer demand, business model, and management execution certainty [1] - WuXi AppTec expects its continuous operating business to return to double-digit growth, with an adjusted growth rate of 17-18%, and overall revenue revised to 43.5-44 billion yuan [1] Group 2 - In terms of profitability, key indicators under three metrics are expected to grow at a rate higher than revenue, with adjusted non-IFRS net profit, net profit attributable to shareholders, and net profit attributable to shareholders after deducting non-recurring gains and losses projected to increase by approximately 41.33%, 102.65%, and 32.56% year-on-year, respectively [1]

Core Viewpoint - WuXi AppTec has reported record-high revenue and profit figures for the fiscal year 2025, with basic earnings per share doubling to 6.70 CNY per share [1] Group 1: Financial Performance - The company achieved historical highs in revenue and profit across three metrics for the fiscal year 2025 [1] - The expected net profit attributable to shareholders for 2025 is projected to lead to a record cash dividend of over 5.7 billion CNY [1] Group 2: Shareholder Returns - WuXi AppTec has maintained a leading cash dividend ratio of 30% since its listing, reflecting its commitment to returning value to shareholders [1] - The anticipated rapid growth in net profit will be shared with shareholders through cash dividends [1] Group 3: Incentive Plans - The company has met the core unlocking conditions for its 2025 H-share incentive trust plan, with revenue targets set at 42 billion CNY and 43 billion CNY for additional stock grants [1] - A total of 2.5 billion HKD in equity incentives is set to be unlocked, aimed at fostering long-term development with core talent [1]

Core Viewpoint - WuXi AppTec has announced a significant increase in both revenue and profit for the fiscal year 2025, indicating strong operational performance and growth potential [1] Financial Performance - The company expects total revenue of approximately 45.456 billion yuan, representing a year-on-year growth of 15.84% [1] - Revenue from continuing operations is projected to grow by 21.4%, showcasing robust development in its core business [1] - Key profit indicators have also seen substantial year-on-year increases, with adjusted non-IFRS net profit, net profit attributable to shareholders, and net profit after deducting non-recurring items growing by 41.33%, 102.65%, and 32.56% respectively [1] - Overall, WuXi AppTec's revenue and three major profit metrics are set to surpass historical peaks, highlighting a trend of high-quality growth [1]

北京商报讯（记者 王寅浩 宋雨盈）1月12日，药明康德发布2025年度业绩预增公告，公司预计2025年实 现营业收入约454.56亿元，同比增长约15.84%；实现经调整归母净利润约149.57亿元，同比增长约 41.33%；实现归属于公司股东的净利润约191.51亿元，同比增长约102.65%。 ...

附："2025中国企业ESG百强"榜 新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务，助力上市公司传播ESG理念，提升ESG可持续发展表现。点 击查看【 ESG评级中心服务手册】 在全球可持续发展浪潮席卷而来的当下，ESG（环境、社会、公司治理）已成为衡量企业高质量发展的核心标尺，更是连接企业价值与社会价值的关键纽 带。随着国内ESG生态体系的加速完善，政策监管持续收紧、资本市场对ESG表现的关注度不断飙升，企业的可持续发展能力愈发成为其核心竞争力的重 要组成部分。 在此行业背景下，新浪财经重磅发布"2025中国企业ESG百强"榜单。该榜单依托新浪财经专业的ESG评级体系，以5000余家A股上市公司及在港上市内地 企业为评价对象，创新性搭建18套行业ESG评价模型，纳入150余项ESG指标，通过量化模型综合演算，对企业ESG表现进行全面、客观的综合评价，最 终筛选出中国ESG实践的标杆企业。榜单不仅为行业树立了发展典范，更为投资者提供了极具参考价值的决策依据。 药明康德在环境、社会、公司治理领域开展了大量工作，积累了丰富的创新实践与扎实的落地成果。凭借在ESG各领域的卓越表现，药 ...

Core Viewpoint - WuXi AppTec (603259.SH) expects to achieve a net profit attributable to shareholders of approximately RMB 19.151 billion in 2025, representing a year-on-year growth of about 102.65% [1] Group 1: Business Model and Strategy - The company continues to focus on its unique "integrated, end-to-end" CRDMO (Contract Research, Development, and Manufacturing Organization) business model [1] - WuXi AppTec is committed to meeting customer demands for empowerment and is continuously expanding new capabilities and building new production capacity [1] - The company is dedicated to optimizing production processes and improving operational efficiency to drive steady business growth [1] Group 2: Commitment to Clients and Market Impact - WuXi AppTec aims to empower clients effectively and is committed to bringing more new and effective drugs to global patients [1]

Core Viewpoint - WuXi AppTec (603259.SH) expects to achieve a net profit attributable to shareholders of approximately RMB 19.151 billion in 2025, representing a year-on-year growth of about 102.65% [1] Group 1: Business Model and Strategy - The company continues to focus on its unique "integrated, end-to-end" CRDMO (Contract Research, Development, and Manufacturing Organization) business model [1] - It is committed to meeting customer demands for empowerment and is continuously expanding new capabilities and building new production capacity [1] - The company aims to optimize production processes and improve operational efficiency to drive steady business growth [1] Group 2: Commitment to Clients and Market - WuXi AppTec is dedicated to empowering clients efficiently and aims to bring more new and effective drugs to patients worldwide [1]